Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 4, 2004, Pages 549-559

  Vainas, I ^a   Koussis, Ch ^b   Pazaitou Panayiotou, K ^b   Drimonitis, A ^b   Chrisoulidou, A ^b   Iakovou, I ^b   Boudina, M ^b   Kaprara, A ^b   Maladaki, A ^b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b NONE

Author keywords

Somatostatin analogue therapy; Somatostatin receptor in vivo

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; OCTREOTIDE; PENTAGASTRIN; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN STEM NEOPLASMS; CALCITONIN; CARCINOMA; CHILD; DRUG MONITORING; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OCTREOTIDE; RADIONUCLIDE IMAGING; RECEPTORS, SOMATOSTATIN; RECURRENCE; SOMATOSTATIN; THYROID NEOPLASMS; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 12544255778     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Schlumberger M. and Pacini F.: Medullary Thyroid Carcinoma. In Thyroid Tumors, Editions Nucleon Paris, Chapter 15: 267-299, 1999.
2. Albores-Saavedra J., Montforte H., Nadji M., et al.: C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum. Pathol. 19: 795-799, 1988.
3. Donovan D.T. and Gagel R.F.: Medullary Thyroid Carcinoma and the multiple Neoplasia Syndromes. In Thyroid Diseases: endocrinology, surgery, nuclear medicine and radiotherapy. 2nd edition, Falk.A (Ed) Lippincott-Raven: 619-644, 1997.
4. Wohllk N., Cote J.G., Evans B.D., et al.: Applications of genetic screening information to management of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2. In: Endocrine and Metabolism Clinics of N. America, Thyroid Cancer II: 1-25, 1996.
5. Serially A.V.: Oncological applications of somatostatin analogs. Cancer Res. 48: 6977-6985, 1988.
6. Mato E., Matias-Guiu X., Chico A. et al.: Somatostatin and Somatostatin Receptor Subtype Gene Expression in Medullary Thyroid Carcinoma. J. Clin. End. Metab. 83, 7: 2417-2420, 1998
7. Lamberts S., Krenning E. and Reubi J.C.: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12: 450-482, 1991.
8. Krausz Y., Rosier A, Guttmann H. et al.: Somatostatin Receptors Scintigraphy for Early Detection of Regional and Distant Metastases of Medullary Carcinoma of the Thyroid. Clin. Nuclear Med. 24, 4:256:260, 1999.
9. 111 In-DTPA-D-Phe] and [123 I-Ty3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. of Nucl. Medicine 20(8): 716-731, 1993.
10. Rufmi V, Salvatori M., Salethich I. et al.: Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tymor Inter. Workshop on "ten years of Experience with MIBG Applications, and the Potentional of New Radiolabeled Peptides", Rome (Italy), 3 June 1994.
11. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptor. Quarterly J. of Nucl. Med. 39 (4) 11: 134-136, 1995.
12. Doerr U., Wurm K., Boring E. et al.: Diagnostic Reliability of Somatostatin Receptor Scintigraphy during continuous Treatment with different Somatostatin Analogs. In Somatostatin Receptor Imaging, Hormone and Metabolic Research, Suppl. Vol. 27: 36-43, G. Thieme Verlag, Stuttgart-New York, 1993.
13. Hoefnagel C.A.: Radionuclide Therapy revisited. Eur. J. Nucl. Med. 18: 408-431, 1991.
14. Reubi J.C., Chayvialle J.A., Franc B. et al.: Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab. Invest. 64: 567-573, 1991.
15. Ain K., Taylor K., Tofiq S. et al.: Somatostatin Receptors Subtype Expression in Human Thyroid and Thyroid Carcinoma Cell Lines. J. Clin. Endocrinol. Metab. 82: 1857-1862, 1997.
16. Dotzenrath C., Goretzki P., Cupisti K., et al.: Is there any consensus in diagnostic and operative strategy with respect to medullary thyroid cancer? A questionnaire answered by 73 endocrine surgical units. Langenbeck's Arch. Surg. 386: 47-52, 2001.
17. Zabel M., Gebarowska E., Drag-Zalesinska M., et al.: Effect of octreotide on proliferation of in vitro cultured thyroid medullary carcinoma cells. Folia Histochemica et Cytobiologica 39(2): 185-186, 2001.
18. Bergholm U., Adami H.O., Bergstroem R. et al.: Clinical characteristics in sporadic and familial medullary thyroid cancer. Cancer 63: 1196-1204, 1989.
19. Gimm O., Ukkat J., Dralle H.: Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J. Surg. 22: 562-568, 1998.
20. Molley J.F. and DeBenedetti M.K.: Patterns of nodal metastases in palpable medullary thyroid cancer. Ann. Surg. 229: 880-888, 1999.
21. Wagner H.E., Ruchti C., Studer M. et al.: Langzeitverlauf des medullaeren Schilddruesenkarzinomes. Swiss Surg. 2: 181-186, 1996.
22. Vainas I., Votsi M., Atmatzidis E. et al.: Calcitonin (CT) stimulation tests in the diagnosis and follow-up of patients with Medullary Thyroid Carcinoma (MTC). Proceedings of Fourth International Congress on Hormones and Cancer:379, Amsterdam/The Nederlands, September 15-19, 1991.
23. Doerr U., Wurstlin S., Frank-Raue K. et al.: Somatostatin Receptor Scintigraphy and Magnetic Resonance Imaging in Reccurent Medullary Thyroid Carcinoma: a Comparative Study In Somatostatin Receptor Imaging, Hormone and Metabolic Research, 27(suppl.): 48-56, G. Thieme Verlag, Stuttgart-New York, 1993
24. Buhr H.J., Kallinowski F., Raue F. et al.: Microsurgical neck dissection for occult metastizing medullary thyroid carcinoma. Cancer 72: 3685-3693, 1993.
25. Tung W.S., Vesely T.M. and Molley J.F.: Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid carcinoma. Surgery 118: 1024-1030, 1995.
26. Learoyd D.L., Roach P.J., Briggs G.M. et al.: Technetium-99m-Sestamibi Scanning in recurrent medullary thyroid carcinoma. J. Nucl. Med. 38: 227-230, 1997.
27. Liewendahl K., Valimaki M., Taatvitsainen M.: Localization of hepatic metastases by radiolabelled anti-carcinoembryonic antigen antibody and meta-iodobenzylguanidine in a patient with MTC. Eur. J. Nucl. Med. 20: 551-554, 1993.
28. Simon G.H., Nitsche E.U., Laubenberger J.J. et al.: PET imaging of recurrent medullary thyroid cancer. Nuklearmedizin 35: 102-104, 1996.
29. Vainas I.: Octreotide in the Management of Hormone Refractory Prostate Cancer. Chemotherapy 47(2): 109-126, 2001.
30. Vainas I., Pasaitou K., Galactidou G. et al.: The role of Somatostatin Analogues in complete antiandrogen treatment in patients with prostatic carcinoma. J. Exp. Clin. Cancer Res. 16/1: 119-126, 1997
31. Siperstein A., Levin K., Gum E. et al.: Effect of Somatostatin on Adenylate Cyclase Activity in Normal and Neoplastic Thyroid Tissue. World J. Surg. 16, 555-561, 1992.
32. Frank-Raue K., Ziegler R., Raue F.: The Use of Octreotide in the treatment of Medullary Thyroid Carcinoma. In: Somatostatin Receptor Imaging, Hormone and Metabolic Research, Suppl. Vol. 27: 44-49, G. Thieme Verlag, Stuttgart-New York, 1993.
33. Clemens D., Webb J., Heath D., et al.: SMS 201-995 and endocrine tumours. Scand. J. Gastroenterol. 119: 251-255, 1986.
34. Geelhood G.W., Bass B.L., Mertz S.L., et al.: Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia. Surgery 100: 962-970, 1986.
35. Jerkins T.W., Sacks H.S., O'Dorisio TM. et al.: Medullary carcinoma of the thyroid, pancreatic nesidioblastosis and microadenosis, and pancreatic polypeptide hypersecretion. A new association and clinical and hormonal responses to long-acting somatostatin analog SMS 201-995. J. Clin. Endocrinol. Metab. 64: 1313-1319, 1987.
36. Modigliani E., Cohen R., Joannidis S. et al.: Results of long-term continuous subcutaneous octreotide administration of 14 patients with medullary thyroid carcinoma. Clin. Endocrinol. (Oxf) 36: 183-186, 1992.
37. Mahler C., Verhelst J., De Longueville M. et al.: Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin. Endocrinol. 33: 261-269, 1990.
38. Gordin A, Lamberg BA, Pelkonen A. et al.: Somatostatin inhibits the pentagastrin induced release of serum calcitonin in medullary carcinoma of the thyroid. Clin. Endocrinol. 8: 289-293, 1987.
39. Guliana J.M., Guilliausseau P.J., Caron J. et al.: Effects of short-term subcutaneous administration of SMS 201-995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma. Horm. Metabol. Res. 21: 584-586, 1989.
40. Libroia A., Verga U., di Sacco G. et al.: Use of somatostatin analog SMS 201-995 in medullary Thyroid Carcinoma. Henry Ford Hosp. Med. J. 37: 151-153, 1989.
41. Schrezemeir J., Plewe G., Sturmer W. et al.: Treatment of APUDomas with long acting somatostatin analogue SMS 201-995. Scand. J. Gastroenterol. 119: 223-227, 1986.
42. Pacini F., Elisei R., Anelli S. et al.: Somatostatin in medullary thyroid cancer- in vitro and in vivo studies. Cancer 63: 1189-1195, 1989.
43. Lupoli G., Cassone E., Arfollar F. et al.: Treatment of Advanced Medullary Thyroid Carcinoma with a Combination of Recombinant Interferon a-2β and Octreotide. Cancer 78: 1114-1118, 1996.
44. Cascone E., Vitale G., Arlotta F. et al.: Effects of one year continuous administration of octreotide and interferon alpha in patients affected by medullary thyroid carcinoma. J. of Endocr. Investigation 19(6) 11: 33 (Abs.65), 1996.
45. Vitale G., Tagliaferri P., Caraglia M. et al.: Slow Release Lanreotide in Combination with Interferon-a2b in the Treatment of Symptomatic Advanced Medullary Thyroid Carcinoma. J. Clin. End. Metab. 85: 983-988, 2000.
46. Diez J.J., Iglesias P.: Somatostatin analogs in the treatment of Medullary thyroid carcinoma J. Endocrinol. Invest. 25(9): 773-778, 2002.
47. O'Byrne K.J., O'Hare N., Sweeney E. et al.: Somatostatin and Somatostatin analogues in medullary thyroid carcinoma. Nuclear Med. Communications 17(1): 810-816, 1996.